Avalo Therapeutics, Inc. (AVTX)

NCM – Real vaqt narxi. Valyuta: USD

19.53

+0.06 (0.31%)

Bozor ochiq: Aug 12, 2026, 3:10 PM EDT

19.47

0.00 (0.00%)

Oldingi bozordan keyin: Aug 11, 2026, 7:34 PM EDT

06.08.2026

Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates

WAYNE, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced business updates and financial results for the second quarter of 2026.

Videolar

No Data

There is no data to display

Press-relizlar

06.08.2026

Avalo Therapeutics, Inc. (AVTX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Avalo Therapeutics, Inc. (AVTX)

Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates

Videolar

No Data

Press-relizlar

Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates

Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates

Videolar

No Data

Press-relizlar

Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates

Search stocks

Avalo Therapeutics, Inc. (AVTX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Avalo Therapeutics, Inc. (AVTX)

Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates

Videolar

No Data

Press-relizlar

Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates

Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates

Videolar

No Data

Press-relizlar

Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates